Mirvetuximab Soravtansine-Gynx: uses, dosing, side effects & brands
Mirvetuximab Soravtansine-Gynx is a medicine sold in the U.S. under one brand, for ovarian epithelial carcinoma, fallopian tube neoplasms and peritoneal neoplasms. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Ovarian Epithelial Carcinoma, Fallopian Tube Neoplasms and Peritoneal Neoplasms
- Available as
- Injectable
- Sold as
- Elahere
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
- Boxed warning
- Boxed warning
How mirvetuximab soravtansine-gynx is dosed
From the FDA label for Elahere (application BLA761310). Other mirvetuximab soravtansine-gynx products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Administer ELAHERE as an intravenous infusion only after dilution in 5% Dextrose Injection, USP. ELAHERE is incompatible with normal saline. ( 2.5 ) The recommended dose of ELAHERE is 6 mg/kg adjusted ideal body weight administered as an intravenous infusion every 3 weeks until disease progression or unacceptable toxicity. ( 2.2 ) Premedicate with a corticosteroid, antihistamine, and antipyretic. ( 2.3 ) Premedicate with an antiemetic, ophthalmic topical steroids, and lubricating eye drops. ( 2.3 , 5.1 ) See full Prescribing Information for preparation and administration instructions and dose modifications for adverse reactions. ( 2 ) 2.1 Patient Selection Select patients for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer with ELAHERE based on the presence of FRα tumor expression [see Indications & Usage ( 1 ) and Clinical Studies ( 14 )] using an FDA-approved test. Information on FDA-approved tests for the measurement of FRα tumor expression is available at http://www.fda.gov/CompanionDiagnostics . 2.2 Recommended Dosage The recommended dosage of ELAHERE is 6 mg/kg adjusted ideal body weight (AIBW) administered once every 3 weeks (21-day cycle) as an intravenous infusion until disease progression or unacceptable toxicity [see Dosage and Administration ( 2.5 )]. Dosing based on AIBW reduces exposure variability for patients…
Mirvetuximab Soravtansine-Gynx side effects
The following adverse reactions are discussed elsewhere in the labeling: Ocular Disorders [see Warnings and Precautions ( 5.1 )] . Pneumonitis [see Warnings and Precautions ( 5.2 )] . Peripheral Neuropathy [see Warnings and Precautions ( 5.3 )] . The most common (≥20 %) adverse reactions, including lab abnormalities, were increased aspartate aminotransferase, fatigue, increased alanine aminotransferase, blurred vision, nausea, increased alkaline phosphatase, diarrhea, abdominal pain, keratopathy, peripheral neuropathy, musculoskeletal pain, decreased lymphocytes, decreased platelets, decreased magnesium, decreased hemoglobin, dry eye, constipation, decreased leukocytes, vomiting, decreased albumin, decreased appetite, and decreased neutrophils. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact AbbVie at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The pooled safety population described in Warnings and Precautions reflect exposure to ELAHERE in 682 patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer at 6 mg/kg AIBW administered…
Who shouldn’t take mirvetuximab soravtansine-gynx
None. None. ( 4 )
Mirvetuximab Soravtansine-Gynx drug interactions
Strong CYP3A4 Inhibitors: Closely monitor for ELAHERE adverse reactions. ( 7.1 ) 7.1 Effects of Other Drugs on ELAHERE Strong CYP3A4 Inhibitors DM4 is a CYP3A4 substrate. Concomitant use of ELAHERE with strong CYP3A4 inhibitors may increase unconjugated DM4 exposure [see Clinical Pharmacology ( 12.3 )] , which may increase the risk of ELAHERE adverse reactions [see Adverse Reactions ( 6 )] . Closely monitor patients for adverse reactions with ELAHERE when used concomitantly with strong CYP3A4 inhibitors [ see Warnings and Precautions ( 5 ) ] .
Every mirvetuximab soravtansine-gynx product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Elahere.
What people report to the FDA about mirvetuximab soravtansine-gynx
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 66 reports naming mirvetuximab soravtansine-gynx, and the FDA flagged 68% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- neuropathy peripheral9 reports
- diarrhoea8 reports
- pneumonitis8 reports
- abdominal pain6 reports
- fatigue5 reports
- keratopathy5 reports
- infusion related reaction4 reports
- keratitis4 reports
Read these as a signal, not a rate. A report does not mean mirvetuximab soravtansine-gynx caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
Related calculators
Frequently asked questions
What is mirvetuximab soravtansine-gynx?
Elahere (Mirvetuximab Soravtansine-Gynx) is a medication used to treat Ovarian Epithelial Carcinoma, Fallopian Tube Neoplasms, Peritoneal Neoplasms.
Can you take mirvetuximab soravtansine-gynx with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run mirvetuximab soravtansine-gynx against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does mirvetuximab soravtansine-gynx come in?
Across the brands we track, mirvetuximab soravtansine-gynx is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic mirvetuximab soravtansine-gynx?
We do not currently list a generic-labelled mirvetuximab soravtansine-gynx product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Mirvetuximab Soravtansine-Gynx: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/mirvetuximab-soravtansine-gynx
- MLA
- “Mirvetuximab Soravtansine-Gynx: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/mirvetuximab-soravtansine-gynx.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for mirvetuximab soravtansine-gynx on DailyMed (NIH) ↗ — including its boxed warning in full.